Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells;

  • Macrophages.
  • NK cells.
  • Dendritic cells.
  • Cytotoxic T lymphocytes.
  • Antibody-producing plasma cells.

Proven in breast cancer cells, but effective in treating all forms of the disease, adoptive T cell-based therapy encourages the body's immune system to attack cancer cells.

Vaxo-Q-Re has been under development by RGCC scientists for more than five years and is now categorized as a cell therapy medicinal product (CTMP) by the European Medicines Agency (EMA).

For more information

Request information without obligation

Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.